Growth Disorders

• EMA withdrawal · 2024-03-14
  EMA Application withdrawn: Vijoice (alpelisib) — Novartis Europharm Limited

  The EMA has withdrawn the application for Vijoice (alpelisib) from Novartis Europharm Limited for genetic diseases and growth disorders.

• EMA withdrawal · 2017-12-01
  EMA Lapsed: Somatropin Biopartners (somatropin) — BioPartners GmbH

  The EMA indicates the Somatropin Biopartners product (somatropin) under BioPartners GmbH has lapsed status.